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Multiple guidelines exist for the follow-up of breast cancer, with no agreement on frequency or duration. The contribution of routine
clinical examination for the detection of potentially treatable relapse, and the impact this has on survival, is unknown. In this study, we
systematically review the literature to establish the proportion of potentially treatable locoregional relapses and new contralateral
breast cancers detected by clinical examination, mammography and patient self-examination. We analyse whether method of
detection of relapse influences outcome. The methods used were systematic review of the literature. MEDLINE, EMBASE, CancerLit,
Web of Sciences and EBM reviews were the data sources for the systematic review. All studies with information on proportion of
relapses detected by clinical examination, mammography and self-examination were included. A total of 30–40% of potentially
treatable relapses are detected by patient self-examination. In studies published before 2000, 15% of such relapse is
mammographically detected with 46% detected by routine clinical examination. In those published after 2000, 40% are
mammographically detected with 15% detected on routine clinical examination. Patients with ipsilateral breast relapse detected
clinically appear to do less well than those with relapse detected by self-examination or mammography. Routine clinical surveillance is
responsible for detection of fewer potentially treatable relapses in more modern cohorts as experience with mammography
increases. There is no evidence to suggest that clinical examination confers a survival advantage compared with other methods of
detection. The data in this analysis suggest that a review of the guidelines on follow-up after breast cancer should be undertaken.
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The early detection of potentially treatable relapse remains a
central purpose of follow-up after breast cancer (National Institute
for Clinical Excellence, 2002). Regular clinical examination and
mammography are recommended to meet this aim.
Although studies suggest that mammography is useful for
detecting metachronous contralateral disease and relapse in the
conserved breast at an early and treatable stage (Mellink et al,
1991; Grunfeld et al, 2002), recent guidelines from the National
Institute for Clinical Excellence (NICE) state that the yield of
mammography in follow-up is low (National Institute for Clinical
Excellence, 2002). The value of clinical examination in detecting
locoregional relapse is less certain, yet it is still valued highly by
those producing guidelines, who recommend regular clinical
examination at least for the first 3–5 years after treatment
(American Society of Clinical Oncology, 1999; National Institute
for Clinical Excellence, 2002; The Association of Breast Surgery @
BASO and Royal College of Surgeons of England, 2005).
Early detection of locoregional relapse has a beneficial effect on
survival (Clark et al, 1985; Recht et al, 1989; Fowble et al, 1990;
Kurtz et al, 1990; Haffty et al, 1991; Dalberg et al, 1998). However,
it is uncertain whether routine clinical examination contributes to
this early detection. Routine clinic visits are stressful for women
attending them. Up to 70% of women report feelings of anxiety
before such visits (Paradiso et al, 1995). While high levels of
anxiety are probably attendant on all stages of the process of breast
cancer diagnosis and treatment, it is not clear in the case of routine
clinic visits whether they are of sufficient value to justify the
anxiety they cause.
The aim of this article is to establish, through a systematic
analysis of the literature, the relative contributions of clinical
examination, patient self-examination and mammography to the
detection of potentially treatable relapse (locoregional and new
contralateral disease) after breast cancer. The impact on survival of
method of detection is also explored.
MATERIALS AND METHODS
MEDLINE, EMBASE, CancerLit, Web of Sciences and EBM reviews
were searched for relevant studies. The original search was
conducted in January 2006 and all English language publications
between 1966 and January 2006 were considered. Two groups of
authors allowed access to further data. Analysis of this further data
led to delay in publication of the review and also led to an original
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sreport in the literature. To ensure an up to date review and to allow
inclusion of the original report in this review without risk of
introducing selection bias, the complete search of the literature
was repeated in May 2007. The search string used is reproduced as
Appendix 1. Both of these initial searches were conducted
independently by authors DAM and KK. Titles were studied to
assess which abstracts should be obtained. For the remainder of
this report, all figures refer to the complete search until May 2007.
All abstracts were read and considered independently by DAM
and KK to establish whether the full text article should be
retrieved. Sources of disagreement at this stage resulted in the full
text article being obtained. References of all full text articles
obtained were also searched for further relevant studies.
Selection criteria
Two separate analyses were conducted; first analysis was a
comparison of methods used to detect relapse and a second
analysis was the effect of method of detection on survival. Studies
were included in a comparison of methods used to detect relapse if:
  The study group comprised women with primary operable
invasive breast cancer without metastatic disease out-with the
breast and axilla at initial presentation.
  Data pertaining to isolated locoregional relapse only were
presented, or such data were presented separately from distant
relapse data. Locoregional relapse was defined as relapse within
the ipsilateral breast or axilla or new contralateral disease.
Supraclavicular lymphadenopathy was considered to be distant
disease for the purpose of this analysis.
  Data for each site of relapse analysed are presented separately.
There may be differences in the pattern of detection of each site
of relapse (ipsilateral breast, contralateral breast or axilla), and
this must be fully explored.
  The method of detection (mammography, symptoms or clinical
examination) of all types of relapse was included.
The authors of studies which contained some relevant informa-
tion were written to for extra data, and the study included if the
author could provide sufficient data to meet the inclusion criteria
above. The studies included in the analysis of methods of detection
were included in the further analysis of survival if there was
adequate data on survival included in the initial paper, or if the
authors were able to supply outcome data after correspondence.
Assessment of methodological quality of included studies
Methodological quality was assessed independently by two authors
(DAM and KK) by means of a pre-defined form. There are no
accepted criteria for measuring methodological quality in prog-
nostic studies and so this form was a modified version of the form
created by de Bock et al (2004), derived from the work by Altman
and Lyman (1998) and Laupacis et al (1994). The form is presented
as Table 1.
When analysing survival, it is of particular concern if patients
who are recognised as having relapse are not analysed. In
retrospective analyses particularly, this may be because the patient
has subsequently died and case notes have been destroyed.
Therefore, when assessing the methodological quality in each
study, we have included the percentage of patients with recognised
relapse not included in the final analysis due to lack of
information.
Data extraction
Two authors, DAM and KK, extracted data from included studies
independently. Data collected were year of publication and year of
initial operation or referral, population size, age, primary therapy,
study design, follow-up schedule including mammographic
schedule, number of locoregional relapses and method of detection
of locoregional relapse (scheduled vs interval clinic and whether
detection was by patient, clinician or mammography in the first
instance).
Relapse was recorded as clinically detected if it was first detected
by a physician in a patient who had not noticed any relevant
symptoms. Relapse was recorded as detected by the patient if
the patient attended clinic with relevant symptoms, whether the
patient waited for the next routine clinic visit or arranged an
interval appointment. It was recorded as mammographically
detected if an abnormal or suspicious mammogram was recorded
before clinical examination revealed any abnormality.
Survival after locoregional relapse was recorded if that
information was available.
Statistical analysis
All data were analysed using SPSS version 11.01 (SPSS Inc.,
Chicago, IL, USA). For survival calculations, individual data were
available for each patient allowing analysis of all individual
patients.
RESULTS
In all, 4061 titles were studied in MEDLINE, 4563 in EMBASE, 8906
in CancerLit and 3144 in Web of sciences. From all EBM reviews
including the Cochrane database, three review articles were
retrieved. From these titles, 188 abstracts were read and considered
independently by DAM and KK. Nine review articles and four
letters or editorials were also obtained from the 188 abstracts to
examine the references of these articles for further relevant studies.
In total, 68 full text articles were considered for inclusion.
From the 68 full text articles considered, 11 studies met the
primary inclusion criteria for our analysis of method of detection
of locoregional relapse (Mohoney, 1986; Tate et al, 1989; Rutgers
et al, 1991; Hussain et al, 1995; Grunfeld et al, 1996; Snee, 1996;
Lees et al, 1997; Jack et al, 1998; Churn and Kelly, 2001; Grogan
et al, 2002; Montgomery et al, 2007b). One of these contained
information on long-term outcome after local relapse detection
(Snee, 1996).
A further 25 studies contained some data appropriate to our
meta-analysis and the authors of these were written to. One was
able to provide us with further information, including method
of detection of local relapse and subsequent outcome for the
complete study group and four additional patients, and has
therefore been included in both analyses (van der Sangen et al,
2006).
From the 12 published studies (Mohoney, 1986; Tate et al, 1989;
Rutgers et al, 1991; Hussain et al, 1995; Grunfeld et al, 1996; Snee,
1996; Lees et al, 1997; Jack et al, 1998; Churn and Kelly, 2001;
Grogan et al, 2002; van der Sangen et al, 2006; Montgomery et al,
2007b), data were available for 7617 patients with 540 relapses.
Seven of these studies (Mohoney, 1986; Rutgers et al, 1991;
Hussain et al, 1995; Jack et al, 1998; Grogan et al, 2002; van der
Sangen et al, 2006; Montgomery et al, 2007b) analysed patients
treated by conservation surgery, two a combination of mastectomy
and conservation surgery (Grunfeld et al, 1996; Churn and Kelly,
2001) and one mastectomy alone (Snee, 1996). Two studies (Tate
et al, 1989; Lees et al, 1997) did not specify original treatment, but
the study by Lees et al (1997) includes ipsilateral breast relapse and
must therefore have included some patients treated by breast
conservation.
Only two studies (Snee, 1996; Montgomery et al, 2007b)
reported survival related to method of detection of relapse in the
original report. One group had published data concerning
outcome after locoregional relapse, and were able to supply us
with the method of detection for all of these relapses after
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sTable 1 Quality rating of included studies
Mahoney
(1986)
Tate
et al
(1989)
Rutgers
et al
(1991)
Snee
(1996)
Hussain
et al
(1995)
Grunfeld
et al
(1996)
Lees
et al
(1997)
Jack
et al
(1998)
Churn
and Kelly
(2001)
Grogan
et al
(2002)
van der Sangen
et al (2006)
Montgomery
et al
(2007a,b)
Is the population under study defined
(with inclusion and exclusion criteria)?
Yes Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes
Is the original cohort of patients from
which those with relapse were drawn
defined?
Yes Yes Yes Yes Yes Yes No Yes Yes Yes No Yes
Were all those identified as having
relapse analysed?
Yes Yes No Yes Yes Yes Yes Yes Yes Yes Yes No
Is loss during follow-up specified? No No No No No Yes No Yes No Yes No No
Are the main prognostic factors defined
(at least age of patient and stage of
tumour)?
No No No Yes No Yes No Yes Yes Yes Yes (personal
communication)
Yes
Is treatment of first tumour specified
(including adjuvant)?
No No Yes Yes Yes Yes No Yes Yes Yes Yes Yes
Is mean or median follow-up greater
than 5 years?
Not given No Not given Yes Yes No Not given Yes Yes Yes Yes Yes
Is the follow-up schedule (including
mammographic interval) specified?
Yes Yes Yes No Yes Yes Yes Yes Yes Yes Yes Yes
Were methods of diagnosis of relapse
prospectively assessed?
Yes Yes No No No Yes No No No No No No
Is all relapse, including axillary and new
contralateral cancers, included?
Not given Yes No Not given Not given Not given Yes Yes No Yes No Yes
Percentage of relapses not analysed
due to inadequate information
0 02 % 000 000 00 3 %
Total score 5 64668 397 96 7
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sTable 2 Characteristics of studies included in methods of detection meta-analysis
Study Year Patient group Relapses included Inclusion period Age Primary therapy Study design Follow-up schedule Mammograms
Mahoney et al1986 273 treated
patients
52 locoregional
relapses.
All ipsilateral breast
All patients treated by
lumpectomy between July
1972 and October 1983.
All relapses from July 1972
to December 1983 analysed.
Not given Lumpectomy Prospective cohort
study of the use of
thermography
Three monthly for 1 year,
four monthly for 1 year, six
monthly for 3 years then
annual
Biennial
Tate et al 1989 510 patients
previously treated for
early breast cancer
attending a follow-up
review during the
inclusion period.
27 locoregional
relapses. Ipsilateral
breast (12), Ipsilateral
axilla (12) and
contralateral breast (3)
6-month period (unspecified)
neither original operation
dates nor date of
relapses specified
At follow-up: mean
65 for interval
attenders, 60 for
symptomatic routine
and 63 for
asymptomatic routine
Not specified Non randomised, non
controlled prospective
cohort
Two monthly for 1 year,
three monthly for 1 year,
four monthly for 1 year six
monthly for 2 years then
annual until 10 years
Not specified
Rutgers et al 1991 44 patients with
locoregional relapse
presenting between
1982 and 1990
44 locoregional
relapses All ipsilateral
breast
All locoregional relapses
diagnosed between 1982
and 1990 from a cohort
of all patients treated
between 1978 and 1990
mean 47.1 (range:
26–68)
Lumpectomy and
axillary dissection
Non randomised, non
controlled
retrospective cohort
Three monthly for
2 years, six monthly
up to 5 years
then annual
Annual
Snee 1994 All 33 patients
referred to regional
centre for adjuvant
treatment.
5 locoregional
relapses chest wall (3)
and axilla (2)
All referrals: jan-feb 1982.
Noinformation given on
original operation date or
period of follow-up
scrutinised.
At referral: mean
57 (range¼34–78)
Mastectomy Non randomised, non
controlled, prospective
cross-sectional
not detailed, mean
of two visits
each per year.
Not specified
Hussain et al 1995 354 treated patients 33 locoregional
relapses. Ipsilateral
breast (24), Ipsilateral
axilla (3) ipsilateral
breast and axilla (6).
Did not include new
contralateral disease
All patients treated
between October 1980
and December 1991. Date
of analysis not given
Not given WLE+radiotherapy+at
least axillary sample
Non randomised,
non controlled
retrospective cohort
3 monthly for 2 years, 6
monthly for 3 years then
annual until 10 years
6 months then
annual
Grunfeld et al 1996 296 patients
randomised to GP vs
hospital follow-up.
7 locoregional relapses
ipsilateral breast/chest
wall (5) and ipsilateral
axilla (2)
All patients treated between
1988 and 1992 were
randomised to the trial at
the end of this period and
followed for
18 months from that point
GP follow-up mean
55.6. Hospital
follow-up mean 59
153 mastectomy and
138 WLE
prospective
randomised
comparison of GP v
hospital follow-up
three monthly for 1 year
and 6 monthly for four in
one group, 3, 4 and 6
monthly years 1, 2 and 3 for
the other then annual both
groups.
Year one then
every 1 to 3 years
Lees et al 1997 A selected group of
458 treated patients.
Selection criteria not
given
83 locoregional
relapses. All ipsilateral
breast
All patients were treated
between 1980 and 1985.
Follow-up complete until
December 1991
Not given Mastectomy or
conservation surgery
Non randomised,
non controlled
retrospective cohort
three monthly for 2 years
then 6 monthly to 5 years
then annual
Annual
Jack et al 1998 341 treated patients 39 locoregional
relapses. Ipsilateral
breast (24), ipsilateral
axilla (11) and
contralateral breast (4)
All patients treated between
1986 and 1990 and followed
for 10 years. Date of analysis
not given
mean 52.2
(range¼24–82)
Wide Local Excision
(WLE)+radiotherapy
Non randomised,
non controlled
retrospective cohort
3-4 monthly for 3 years,
then 6 monthly
until 10 years
Annual
Churn and
Kelly
2001 All 612 patients with
early breast cancer
referred to regional
oncology centre for
adjuvant therapy in
1993
34 locoregional
relapses. 25 in WLE
group and 9 in
mastectomy group.
Ipsilateral breast, axilla
or chest wall (not
separated, but did not
include new
contralateral disease)
All referrals received in 1993
for adjuvant therapy were
analysed during 1996
189 patients
o50, 423 patients
450
105 mastectomies,
511 conservation,
3 radiotherapy
after neo adjuvant
chemotherapy. Variable
LN dissection
Non randomised,
non controlled
retrospective cohort
3 to 4 monthly for 2–3
years, 6 monthly to
5 years then annual
Less than annual,
according to
clinician
preference
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Clinical Studiescorrespondence (van der Sangen et al, 2006). In total, there are 217
locoregional relapses or new contralateral cancers from a cohort of
4625 patients for whom we were able to establish the method of
detection of relapse, site of relapse and survival.
Characteristics of all the included studies are presented as
Table 2. In particular, Table 2 describes the proportion of relapses
detected in the ipsilateral breast, the ipsilateral axilla and the
contralateral breast for each included study.
Quality rating of studies
The median quality score was 6.33 out of 10 with a range from 3 to
9. Five of the 12 studies included new contralateral breast cancers
in the analysis. Ten of the 12 included studies analysed all of the
locoregional relapses, which they were aware of within their
cohort. In the two remaining studies, one failed to analyse 2%
of relapses (Rutgers et al, 1991) and one failed to analyse 3% of
relapses due to inadequate information on method of detection of
relapse (Montgomery et al, 2007b).
Method of detection of relapse
The proportion of relapses detected by patient symptoms,
mammography and routine clinical examination for each of the
studies is presented in Table 3. For Churn and Kelly (2001), data
were presented separately for mastectomy and for conservation
surgery and so these results are presented separately in the table.
Most of the studies were retrospective analyses and in some cases
it was not certain how the relapse was detected. These are included
in the table as unknown. Relapse detected during further surgery
for cosmetic reasons are described as incidental relapses.
Two studies had separate data available to allow analysis of
relapse after mastectomy alone (Snee, 1996; Churn and Kelly,
2001). It is not clear what initial surgery was employed in the study
by Tate et al (1989), but it is likely to have been mastectomy given
the date of publication. Clinical examination was an important
method of relapse detection in patients after mastectomy, with
between 41 and 66% of relapses detected this way. Mammography
played no role in the detection of relapse in these studies, as new
contralateral disease was not included in any of the analyses. There
have been no more recent studies of relapse in patients treated by
mastectomy.
Three studies reported on locoregional relapse in a mixed
treatment population (Grunfeld et al, 1996; Lees et al, 1997; Churn
and Kelly, 2001). In two studies, it was not possible to separate
patients treated by mastectomy from those treated by wide local
excision (Grunfeld et al, 1996; Lees et al, 1997). Discerning a
pattern of relapse detection in these studies is difficult as
mammography plays a much smaller role in the follow-up of
patients treated with mastectomy than in those treated with breast
conservation. However, clinical examination detected a smaller
proportion of relapses in these studies than in the mastectomy
studies, with less than one-third of relapses detected this way.
There were eight studies which looked at the issue of relapse
after breast-conserving surgery (Mohoney, 1986; Rutgers et al,
1991; Hussain et al, 1995; Jack et al, 1998; Churn and Kelly, 2001;
Grogan et al, 2002; van der Sangen et al, 2006; Montgomery et al,
2007b). In these eight studies, 38% of relapses were detected by the
patient, 30% by mammograms and 28% by clinical examination. In
4%, method of detection was unknown.
There was some temporal overlap between these eight studies
both with regards to the dates when the included patients had been
treated and when relapse was diagnosed. Moreover, the date of
relapse of included patients is not always clear in the included
studies. The information which does exist is included in Table 2.
An attempt was made to assess whether mammography has made a
changing contribution to relapse detection over time. Comparison
was made of the proportion of relapses detected by each method in
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sthe studies of relapse after breast-conserving surgery published
prior to 2000, compared with those published after 2000. Date of
publication was chosen as a surrogate for date of diagnosis of
relapse as it was the only consistent date available for all the
published studies (see Table 2). It is likely to underestimate any
increase in the importance of mammography as the paper by
Churn and Kelly (2001) was published in 2001, yet the analysis
included relapse diagnosed only until 1996 and has a pattern of
relapse similar to that seen in studies published before 2000. The
impact of the study by Grogan et al (2002) is limited as so few
patients are included. While the proportion of relapses detected by
the patient remains fairly constant (39% in studies from those
published before 2000, 37% from those published after), the
proportions detected by mammography and clinical examination
reverse. Before 2000, 15% of relapse was mammographically
detected with 46% detected by routine clinical examination. After
2000, 40% is mammographically detected with 15% detected by
routine clinical examination.
Three of the studies reported only on ipsilateral breast relapse
after wide local excision (Mahoney, 1986; Rutgers et al, 1991; van
der Sangen et al, 2006). In three other studies (Jack et al, 1998;
Grogan et al, 2002; Montgomery et al, 2007b), it was possible to
extract individual data on method of detection for each area of
relapse. Table 4 displays method of detection of ipsilateral breast
relapse, Table 5 displays axillary relapses and Table 6 new
contralateral breast cancers.
Two patients from Montgomery et al (2007b) had simultaneous
bilateral breast relapse and so are not included in these tables. Both
had their relapses detected by mammography.
As can be seen in Table 4, there is a trend towards increasing
proportions of ipsilateral breast relapses being detected by
mammography the more recently published the study. In contrast,
clinically detected ipsilateral breast relapse becomes less common
in more contemporary cohorts.
Very little pattern can be made of axillary relapse, shown in
Table 5, as numbers are small. However, the two larger studies in
Table 5 are from the same unit and, at least within that unit, fewer
axillary relapses are detected by clinical examination in the more
recent cohort (Jack et al, 1998; Montgomery et al, 2007b).
Very few contralateral breast cancers are detected by clinical
examination. A total of 66.6% are detected by mammography and
24.4% by the patients themselves.
Survival
Outcome data were available from three studies within our analysis
(Snee, 1996; van der Sangen et al, 2006; Montgomery et al, 2007b).
In one study, primary surgery was mastectomy in all cases (Snee,
1996). In the other two studies (van der Sangen et al, 2006;
Montgomery et al, 2007b), patients were initially treated by wide
local excision.
Mastectomy
Snee reported on five patients who had suffered locoregional
relapse after mastectomy (Snee, 1996). Two patients with
ipsilateral axillary relapse were diagnosed by clinical examination,
one in the breast clinic and one incidentally at another surgical
clinic. Three patients had chest wall relapse, two with symptoms
and one diagnosed clinically. There was no difference in survival
related to method of detection or area of relapse, although three
patients died within 2 years of relapse. However, there were very
few relapses in this study (Snee, 1996).
Conservation surgery
van der Sangen et al (2006) provided survival data and data on
method of detection of relapse for 86 patients who developed
ipsilateral breast relapse more than 5 years after wide local
excision, method of detection of relapse being unknown in 16 of
their cohort. In Montgomery et al (2007b), method of relapse
detection and survival was known for all 110 patients. Two patients
Table 3 Method of detection of all locoregional relapses for all studies
Initial surgery
Number of
patients
in study
Total number of
patients with
relapse
Patient
detected
relapses
Mammographically
detected
relapses
Clinical
examination
detected relapses
Unknown or
incidental relapse
detection
Tate et al (1989) Not given 510 27 16 (59%) 0 11 (41%) 0
Churn and Kelly,
2001
Mastectomy 105 9 1 (12%) 0 6 (66%) 2 (22%)
Snee 1994 Mastectomy 33 5 2 (40%) n/a 3 (60%) 0
Lees et al (1997) Mastectomy and
conservation
438 83 46 (55%) 15 (18%) 22 (27%) 0
Grunfeld et al
(1996)
Mastectomy and
conservation
296 7 2 (28.66%) 2 (28.66%) 2 (28.66%) 1 (14%)
Mahoney (1986) Conservation 273 52 20 (38%) 1 (2%) 31 (60%) 0
Rutgers et al
(1991)
Conservation 44 44 26 (59%) 8 (18%) 10 (23%) 0
Hussain et al
(1995)
Conservation 354 33 4 (12%) 5 (15%) 24 (73%) 0
Jack et al (1998) Conservation 341 39 15 (38%) 12 (31%) 12 (31%) 0
Churn and Kelly,
2001
Conservation 511 25 9 (36%) 7 (28%) 8 (32%) 1
Grogan et al
(2002)
Conservation 104 4 2 (50%) 2 (50%) 0 0
van der Sangen
et al (2006)
Conservation 3280 102 41 (41%) 32 (32%) 13 (13%) 16 (16%)
Montgomery
et al (2007)
Conservation 1312 110 37 (33.5%) 56 (51%) 15 (13.5%) 2 (2%)
Total 7601 540 221 (41%) 135 (25%) 162 (30%) 22 (4%)
Follow-up in breast cancer
DA Montgomery et al
1637
British Journal of Cancer (2007) 97(12), 1632–1641 & 2007 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
swere excluded from this analysis, having had relapse detected
incidentally (Montgomery et al, 2007b). In total, therefore, method
of detection of relapse and long-term outcome is known for 194
patients from these two studies, and is presented below.
Conservation surgery: ipsilateral breast relapse
Figure 1 shows survival from time of original operation for all
patients with ipsilateral breast relapse only.
There is a trend towards lower 10-year survival from original
diagnosis in women whose relapse is detected clinically compared
with either mammographically detected or detected by the patient,
but this difference has disappeared by 15–20 years and overall
there is no significant difference in survival between the three
groups. This is similar for survival from the time of relapse also
(Figure 2).
Conservation surgery: ipsilateral axillary relapse
There were 25 patients who relapsed in the ipsilateral axilla alone
for whom survival data were available. There was no significant
difference in overall survival related to method of detection of
relapse. There was no difference in time to diagnosis of axillary
relapse or in time from relapse to death among the methods of
diagnosis either. Numbers were very small in each group, however.
Conservation surgery: contralateral breast relapse
There were 35 patients with a new contralateral breast cancer in
whom survival data were available. Overall 5-year survival from
diagnosis of contralateral breast primary was 82.65%.
Twenty-five of these new contralateral cancers were detected
mammographically and 5-year survival from diagnosis of new
cancer in these patients was 85.8%. There were eight new cancers
Table 4 Method of detection of all ipsilateral breast relapses in conservation surgery studies
Number of
patients
in study
Total number of patients
with relapse
Patient
detected Mammographic
Clinical
examination
Unknown or
incidental
Mahoney, 1986 273 52 20 (38%) 1 (2%) 31 (60%) 0
Rutgers et al (1991) 44 44 26 (59%) 8 (18%) 10 (23%) 0
Jack et al (1998) 341 24 9 (37.5%) 9 (37.5%) 6 (25%) 0
Grogan et al (2002) 104 3 1 (33%) 2 (66%) 0 0
van der Sangen et al (2006) 3280 102 41 (41%) 32 (32%) 13 (13%) 16 (16%)
Montgomery et al (2007) 1312 48 17 (36%) 25 (52%) 4 (8%) 2 (4%)
Table 5 Method of detection of axillary relapse
Patient
detected Mammographic
Clinical
examination Total
Jack et al (1998) 4 (36%) 1 (9%) 6 (55%) 11
Grogan et al (2002) 1 0 0 1
Montgomery et al
(2007)
12 (48%) 4 (16%) 9 (36%) 25
Total 17 (46%) 5 (13.5%) 15 (40.5%) 37
Table 6 Method of detection of new contralateral primaries
Patient
detected Mammographic
Clinical
examination Total
Jack et al (1998) 2 2 0 4
Grogan et al (2002) 0 0 0 0
Montgomery et al
(2007)
82 5 2 3 5
Total 10 (26%) 27 (69%) 2 (5%) 39
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Figure 1 Survival from original operation by method of relapse detection (ipsilateral breast relapses only).
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two women whose new cancer was detected first by clinical
examination. Both were alive and well at the time of analysis. There
was no significant difference in overall survival or survival from
time of diagnosis of new contralateral cancer by method of
diagnosis. The number of new cancers diagnosed by means other
than mammography was small, however.
DISCUSSION
Follow-up in breast cancer continues to be an area of importance,
both clinically and economically. Current guidelines published by
the American Society of Clinical Oncology (ASCO) recommend
frequent visits for routine clinical examination and mammography
for up to 10 years after treatment (Khatcheressian et al, 2006).
Clinic attendance for examination was suggested three to four
monthly for 3 years, four to six monthly for two further years and
then annually for 5 more years. There is particular emphasis on
follow-up in the first 3 years after treatment as the rate of relapse
has been reported to be particularly high at this time (Hussain
et al, 1995; Saphner et al, 1996).
In contrast to the ASCO guidelines, The National Institute for
Clinical Excellence (NICE) in England and Wales recommend that
follow-up should be limited to the first 2–3 years after treatment
followed by discharge to general practice (National Institute for
Clinical Excellence, 2002). NICE estimate the cost savings to be
around d3.7 million if follow-up were limited to 5 years, and d9.3
million total savings if follow-up were limited to just 3 years
(National Institute for Clinical Excellence, 2002). These cost
savings are controversial, however, as they are not balanced by
the potential increased costs of late diagnosis of relapse in women
who relapse after 3 years.
Both the ASCO and NICE guidelines have in common the fact
that emphasis is placed on providing frequent clinical examination
in the first 3–5 years after diagnosis. However, this approach is in
disagreement with the findings in this review. There certainly is an
increase in the hazard rate for relapse in the first 3 years after
treatment (Hussain et al, 1995; Saphner et al, 1996). It is likely that
this represents partly a peak in distant relapse and partly a failure
on behalf of previous investigators to include new contralateral
cancers as a form of relapse. In the analysis by Montgomery et al
(2007b), there is an initial peak in rate of distant relapse between 2
and 3 years at around 3% of patients per year. This falls to around
2% per year where it remains constant for almost 10 years. In
contrast, potentially treatable relapse occurs at a constant rate of
1–1.5% per year for at least 10 years (Montgomery et al, 2007b).
Since the aims of follow-up as stated by NICE include the detection
of potentially treatable locoregional disease only and not distant
metastases (National Institute for Clinical Excellence, 2002), there
is no justification to discharge at 2–3 years.
However, doubt remains over the value of the ASCO approach of
providing regular clinical examination after breast-conservation
surgery in the long term. Such examination is responsible for
detection of only 13% of the relapses overall in the two most
contemporary data sets analysed (van der Sangen et al, 2006;
Montgomery et al, 2007b). Moreover, patients who develop
ipsilateral breast relapse that is diagnosed clinically appear to do
less well than patients whose relapse is diagnosed by other means.
There was significantly reduced survival in patients with clinically
diagnosed ipsilateral breast relapse compared with mammo-
graphically or self-detected in the study by Montgomery et al
(2007b). While this was not reflected in our analysis here, this may
be because the study by van der Sangen et al (2006) did not include
relapses diagnosed within the first 5 years after treatment. This
group report a very high survival in patients diagnosed more than
5 years after treatment and so method of detection may be less
relevant after this time.
This review indicates that in both the conserved breast and the
contralateral breast, the contribution of mammography appears
not only to be important, but in fact may be of increasing
importance. While early studies such as those by Mahoney (1986)
reported very few relapse detections using mammography, the
proportion of relapses detected this way has increased so that in
the studies published since 2000, up to 50% of all treatable breast
relapses have been diagnosed first on mammography (Churn and
Kelly, 2001; Grogan et al, 2002; van der Sangen et al, 2006;
Montgomery et al, 2007b). Further work is needed to assess this in
more detail as there was overlap between the studies in terms date
of diagnosis of relapse. It would be useful to assess the proportion
of relapse diagnosed mammographically each year in a large
cohort to confirm the impressions of this analysis.
This change in the impact of mammography is highlighted when
comparing two cohorts treated by breast-conserving surgery at
the same unit. The number of treatable relapses diagnosed by
mammography in Edinburgh has increased from 31% among
patients with relapse diagnosed between 1986 and 1998 (Jack et al,
1998) to 46% in a more recent cohort diagnosed between 1991 and
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Figure 2 Survival from recurrence by method of relapse detection (ipsilateral breast relapses only).
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technical improvements in mammography as well as better quality
assurance. As a result, mammography detected 5.37 new cancers
per thousand routine mammograms undertaken during follow-up
in the most recent Edinburgh cohort (Montgomery et al, 2007b),
which compares very favourably with the observed rate at
incidence screening within the NHS breast screening programme
in the UK (NHS Cancer Screening Programmes, 2003). This fully
justifies the recommendations in the ASCO guidelines for
providing annual mammography, and goes some way to answering
the concerns of the Canadian Steering committee who highlight the
lack of high quality evidence in the literature on which to base
recommendations for mammography (Grunfeld et al, 2005).
Interestingly, the proportion of relapses detected by patients,
particularly in the treated breast, has remained fairly constant at
30–40% throughout all the studies analysed here. This applies
particularly to ipsilateral breast relapse and axillary relapse. It
applies less to contralateral breast relapse, where mammography
has a much larger impact, and this may reflect high pick up from
mammography, less aggressive contralateral disease or simply a
lack of patient awareness of the risk of contralateral breast relapse.
There is great disparity between the findings of this analysis and
the statements by NICE. NICE base their recommendations for
follow-up on the findings of just one retrospective analysis
(Donnelly et al, 2001), a study which was not included in our
analysis due to lack of clarity of the data. The authors of this
review report method of detection of relapse in 67 patients who
developed metastatic disease and 41 locoregional relapses or new
contralateral cancers. Follow-up was for a median of 3 years and 11
months. The authors report that 28 of the locoregional relapses
were symptomatic and that 7 were diagnosed clinically. Two were
discovered with imaging, but not mammography. The pattern of
relapse detection in this cohort is very different from that reported
in any of the cohorts we have analysed here.
Much of the data in this review, particularly data relating to
survival by method of detection of relapse, have come from
unpublished data (van der Sangen et al, 2006; Montgomery et al,
2007b). There are only 10 studies in the literature which fully
present the pattern of relapse after breast cancer with regards to
how that relapse is detected. Only one of these (Lees et al, 1997)
reports on more than 50 patients and only one (Snee, 1996) has
any survival data. A recent systematic review of randomised-
controlled trials of alternative follow-up methods by ourselves
reveals that there are no randomised trials in the literature with
sufficient power to inform the guidelines (Montgomery et al,
2007a). Previous guidelines have not been based on much
evidence.
SUMMARY
Treatable relapse is not common, affecting only 1–1.5% of women
per year (Montgomery et al, 2007b). Such relapse occurs at a
constant rate after treatment, so the majority of relapses occur
more than 3 years after treatment. Patients with later relapses can
expect to do particularly well, and so effort should be made to
diagnose later relapse at an early stage. If any follow-up for the
detection of treatable relapse is to be offered, this cannot stop at
3 years.
The need for clinical follow-up for the detection of relapse is
uncertain. The majority of relapses are now detected by patients or
mammography. Mammography in fact has a very high yield when
conducted annually. There are few relapses detected by clinical
examination and, certainly in the case of ipsilateral breast relapse,
those which are diagnosed clinically may do less well.
Isolated axillary relapse is very uncommon, and it may be that
better patient education could increase the proportion of such
relapse detected by the patient. While most women are well
schooled in breast self-examination, it may be that the importance
of axillary examination is less well appreciated.
Future guidelines should take these facts into account, but
should also try to address the additional needs of patients during
follow-up for breast cancer. These include both detection of
psychosocial problems and side effects of treatment which are
central to maintaining patients well being.
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headings, h4eading word, drug trade name, original title, device manufacturer,
drug manufacturer name]
3 1 and 2
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5 3 and 4
6 Diagnosis or mammogr$ or examin$
7 5 and 6
Follow-up in breast cancer
DA Montgomery et al
1641
British Journal of Cancer (2007) 97(12), 1632–1641 & 2007 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s